Skip to content
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Search
Advanced Search
Menu
JCP
PCC
News
CME
About
Authors & Reviewers
Sign In
Subscribe
Clinical Topics
View All
Addiction
Anxiety
Bipolar Disorder
Depression
Difficult to Treat Depression
Neurology
OCD
Psychopharmacology
PTSD and Trauma
Schizophrenia
Tardive Dyskinesia
View All
Collections
View All
Academic Highlights
Auvelity: Information from Industry
Banner Alzheimer’s Institute
Clinical & Practical Psychopharmacology
Early Career Psychiatrists
Focus on Childhood and Adolescent Mental Health
Focus on Geriatric Psychiatry
Focus on Psychotherapy
Focus on Suicide
Focus on Psychosis
Focus on Women’s Mental Health
Rounds in the General Hospital
James M. Youakim, MD
JCP
Original Research
Adjunctive Brexpiprazole 1 and 3 mg for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Phase 3, Randomized, Double-Blind Study
September 23, 2015
Michael E. Thase
,
James M. Youakim
,
Aleksandar Skuban
, et al
JCP
Original Research
Efficacy and Safety of Adjunctive Brexpiprazole 2 mg in Major Depressive Disorder: A Phase 3, Randomized, Placebo-Controlled Study in Patients With Inadequate Response to Antidepressants
September 23, 2015
Michael E. Thase
,
James M. Youakim
,
Aleksandar Skuban
, et al
JCP
Original Research
Adjunctive Armodafinil for Schizophrenia
August 24, 2010
Read a full article on the efficacy and safety of adjunctive armodafinil therapy for cognitive deficits from schizophrenia.
John M. Kane
,
Deepak C. D' Souza
,
Ashwin A. Patkar
, et al
JCP
Original Research
Adjunctive Armodafinil for Major Depressive Episodes Associated With Bipolar I Disorder: A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Proof-of-Concept Study
July 27, 2010
Joseph R. Calabrese
,
Terence A. Ketter
,
James M. Youakim
, et al
